Xvivo Perfusion ABXVIPF -1.32%87 3-1 Month Momentum % is 53.47% as of Jun. 29, 2026. GuruFocus rates XVIPF with a GF Score™ of 87/100 and a GF Value™ of $47.23 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 91.26% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-06-29), Xvivo Perfusion AB's 3-1 Month Momentum % is 53.47%.
The industry rank for Xvivo Perfusion AB's 3-1 Month Momentum % or its related term are showing as below:
XVIPF's 3-1 Month Momentum % is ranked better than 91.26% of 847
companies
in the Medical Devices & Instruments industry
Industry Median: -1.96
vs XVIPF: 53.47
Xvivo Perfusion AB (OTCPK:XVIPF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Xvivo Perfusion AB 3-1 Month Momentum % Related Terms
XVIPF vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's 3-1 Month Momentum % falls into.
Xvivo Perfusion AB (OTCPK:XVIPF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a 3-1 Month Momentum % of 53.47% as of Jun. 29, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #74 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is Xvivo Perfusion AB's 3-1 Month Momentum % too high?
Xvivo Perfusion AB's current 3-1 Month Momentum % is 53.47%. Based on the distribution chart, Xvivo Perfusion AB ranks #74 out of 847 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #74 out of 847 companies for 3-1 Month Momentum %. This places Xvivo Perfusion AB in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current 3-1 Month Momentum % is 53.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.23, compared to a current price of $29.00 — trading 38.6% below its estimated fair value. The current 3-1 Month Momentum % is 53.47%. Xvivo Perfusion AB's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current 3-1 Month Momentum % is 53.47% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 38.6% below its estimated GF Value™ of $47.23.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
3-1 Month Momentum %: 53.47%
GF Value™: $47.23 vs. price of $29.00 (38.6% below fair value)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
87GF Score
Get the complete analysis for XVIPF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 